We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Novel Procedure Seals Corneal Perforations

By HospiMedica International staff writers
Posted on 15 Apr 2013
A combination of an autologous fibrin membrane and platelet-rich plasma (PRP) appears to be safe and effective for treating perforated corneal ulcers, according to a new study.

Researchers at Vissum Corporación Oftalmológica (Alicante, Spain) conducted a study involving 11 patients to evaluate the use of autologous eye platelet-rich plasma (E-PRP) in combination with an autologous fibrin membrane as a surgical alternative for wound closure in perforated corneal ulcers; both the fibrin membrane and the E-PRP clot were prepared with the patient's own blood before the operation. More...
Nylon stitches were used to fixate the fibrin membrane to the conjunctiva, and the E-PRP clot was placed over the corneal perforation, underneath the fibrin membrane; a temporal partial tarsorrhaphy was performed at the end of the procedure.

The results showed that in all cases the corneal perforation was sealed, with the fibrin membrane present over the corneal surface for the first 3-5 days, and then gradually disappearing. No evidence of infection or inflammation was detected. Digital tonometry confirmed acceptable levels of ocular tonus in all cases from day 2 after the operation. No patients reported pain, discomfort, or other symptoms, and no complications were observed. After three months' follow-up, there was no evidence of relapses or perforations. Corneal grafting was eventually performed in 7 of the 11 cases. The study was published online on April 4, 2013, in JAMA Ophthalmology.

“Platelets play a central role in hemostasis, promoting coagulation in vascular injuries. At the same time, platelets constitute natural reservoirs of growth factors, cell adhesion molecules, and cytokines stored in their alpha granules,” said lead author Jorge Alió, MD, PhD. “Between these growth and mitogenic factors are epidermal growth factors, platelet-derived growth factors, fibroblast growth factors, insulin-like growth factors, and transforming growth factors.”

“They also contain important cell adhesion molecules, such as fibrin, fibronectin, and vitronectin, which enhance growth factor activities. The release of these molecules at the site of injury helps initiate and modulate wound healing, thus promoting tissue reparation in both soft and hard tissues,” concluded Dr. Alió and colleagues. “We assume that this formulation contains the proper growth factors of blood and platelets, although their concentration was not measured in this study.”

Corneal perforations can be caused by trauma or ulcerative disease and constitute a major ophthalmic emergency necessitating the intervention of corneal surgeons. Major consequences of the perforation following such as infection include severe anatomic distortion of the anterior segment of the eye, retinal detachment, phthisis bulbi, and total blindness.

Related Links:

Vissum Corporación Oftalmológica




Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.